Associate Professor, Pathology, Ohio State University College of Medicine
Pathology
Dr. Haifeng M. Wu, MD
|
|
Give Review
Haifeng M. Wu, MD works in the field of Pathology. He attended China Medical University Shenyang. Haifeng M. Wu, MD is a published doctor as well. He has 40 publications published. The latest was: Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. He is registered with Medicare.
Publications
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
- Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.
- Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers.
- Unconjugated Bilirubin Inhibits Proteolytic Cleavage of von Willebrand Factor by ADAMTS13 Protease.
- Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies.
- Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.
- Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP.
- How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.
- Diagnosis and management of complement mediated thrombotic microangiopathies.
- Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies.
- Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
- Complement Activation and Mortality During an Acute Episode of Thrombotic Thrombocytopenic Purpura.
- Practical Issues in ADAMTS13 Testing and Emerging Therapies in Thrombotic Thrombocytopenic Purpura.
- ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.
- Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.
- ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy.
- Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.
- Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
- TTP disease course is independent of myeloma treatment and response.
- Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) m...
- Rapid multiplexed genotyping for hereditary thrombophilia by SELDI-TOF mass spectrometry.
- Personalized healthcare in clotting disorders.
- Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
- D-dimer level and the risk for thrombosis in systemic lupus erythematosus.
- Rapid determination of ADAMTS13 activity improves clinical decision-making.
- Immunotherapy for thrombotic thrombocytopenic purpura.
- Toward functional proteomics of alveolar macrophages.
- Proteome comparison of alveolar macrophages with monocytes reveals distinct protein characteristics.
- Arginine 25 and Arginine 28 of lactoferrin are critical for effective heparin neutralization in blood.
- Gender Differences in Pulmonary Function, Respiratory Symptoms, and Macrophage Proteomics among HIV-Infected Smokers.
- Two-dimensional gel proteome reference map of blood monocytes.
- Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura.
- Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
- Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
- Distinct proteome features of plasma microparticles.
- An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.
- Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.
- Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.
- Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura.
Doctors Specialties
- Pathology
Accepted Insurances
Education
-
New York Presbyterian Hospital -
Duke University Hospital -
China Medical University Shenyang
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871668004 |
| Last Name Of The Provider | WU |
| First Name Of The Provider | HAIFENG |
| View All |
Similar Doctors
|
Dr. Peter B. Baker, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephanie D. Norwood, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anjali A. Satoskar, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Wei Chen, MD |
|
|
Dr. Noman I. Malik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mitchell L. Weinberg, MD |